The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies

Neurobiol Dis. 2009 Sep;35(3):348-51. doi: 10.1016/j.nbd.2009.05.018. Epub 2009 Jun 6.


It has been suggested, based on rodent studies, that levodopa (L-dopa) induced dyskinesia is associated with a disrupted blood-brain barrier (BBB). We have investigated BBB integrity with in vivo neuroimaging techniques in six 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned primates exhibiting L-dopa-induced dyskinesia. Magnetic resonance imaging (MRI) performed before and after injection of Gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) revealed an intact BBB in the basal ganglia showing that l-dopa-induced dyskinesia is not associated with a disrupted BBB in this model.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Antiparkinson Agents / adverse effects*
  • Antiparkinson Agents / therapeutic use
  • Blood-Brain Barrier / pathology*
  • Brain / blood supply
  • Brain / pathology
  • Dyskinesia, Drug-Induced / pathology*
  • Gadolinium DTPA
  • Levodopa / adverse effects*
  • Levodopa / therapeutic use
  • Macaca fascicularis
  • Magnetic Resonance Imaging
  • Male
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / pathology
  • Time Factors


  • Antiparkinson Agents
  • Levodopa
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Gadolinium DTPA